Diabetes Prevention and Prediabetes Management in Adult (PRIME)

May 5, 2025 updated by: Shaun Lee Wen Huey, Monash University

Addressing Disparity in Diabetes Prevention Through Digital Health Supported PRe-diabetes Intervention, Management and Evaluation (PRIME) Program Based in Malaysian Community Pharmacies: A Pilot Study

Currently, an estimated 3.9 million Malaysians continue to live with diabetes with many more who live with prediabetes. Diabetes was the one of the leading causes of death in the Malaysia and the leading cause for kidney failure, lower-limb amputations, and adult-onset blindness. Heart disease and stroke are two to four times more likely for individuals with diabetes. The use of mHealth or mobile health application can reduce blood sugar among individuals with prediabetes but also prevent a later occurrence of diabetes. In this study, the investigators aim to develop and evaluate the effectiveness of a digital health supported pre-diabetes management program based in an urban community pharmacy setting

Study Overview

Status

Completed

Conditions

Detailed Description

Pre-diabetes is an intermediate state of hyperglycaemia with glycaemic parameters above normal but below the type 2 diabetes mellitus (T2DM) threshold. It was estimated that >25% of individuals who are pre-diabetic convert to T2DM within 3-5 years and 70% of individuals with pre-diabetes will develop into full-fledge T2DM within their lifetimes. According to the 2017 estimate, the disease burden of pre-diabetes at Western Pacific region was 7.6% (126.7 millions). The situation is more alarming in Malaysia where a national pre-diabetes prevalence of 22.1% was noted. Currently available support and self-care services offered in Public Hospitals such as the Diabetes Mellitus Treatment Adherence Clinics (DMTAC) are managed based on the in-person appointment basis. Most of the clinics are available only in specific locations. The need to travel long distance as well as long waiting hours has deterred the success of the programs. This is particularly true for the urban poor who are less likely to take time off from work than those from the higher income group. It is also noteworthy to state that the management program when available, generally target the diagnosed T2DM patients.

Studies have shown that individuals with pre-diabetes can substantially reduce their risk of progression to T2DM via participation in evidence-based lifestyle change programs. Previous reports have recorded 54-58% reduction in risk for development to T2DM over 1-3 years with the protective benefit persisting up to 10 years following completion of the program. However, there are several considerations when implementing effective lifestyle intervention program among the pre-diabetes populations in Malaysia. The intervention program should easily be accessible and not confined to public primary and secondary healthcare centres which are already suffering from an overcapacity. Furthermore, consultation should be provided by properly trained healthcare professionals while the ease of communication between the patients and the "lifestyle coach" should be made available.

The advancement of information technology coupled with the increasing availability and acceptance of internet and mobile devices provide useful opportunities for application of wireless and mobile technology in order to enhance self-management of chronic conditions. The incorporation of digital technologies can improve patient adherence and facilitate real-time monitoring of vital biological measurements (i.e. via wearable). Additionally, the "mobile health" (mHealth) services are easily scalable, thus providing opportunities to a greater public accessibility and narrow the disparity in access to disease management. In this study, the investigators propose to pilot a digital health supported pre-diabetes management program based in an urban community pharmacy setting

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Selangor
      • Subang Jaya, Selangor, Malaysia, 47500
        • School of Pharmacy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged 18 years and above
  • BMI 23 and above
  • HbA1c 5.7 - 6.3%

Exclusion Criteria:

  • Unable to give informed consent
  • Pregnant or lactating
  • Established diabetes
  • Terminal illness
  • Does not own a mobile phone
  • Plans to relocate to an area or travel plans that do not permit full participation in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention arm
Participants receiving the phone app together with a fitness tracker. All participants will receive the educational curriculum over a period of 4 weeks through the app. The mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve goals. The participant can use the app to log their food intake, weight, steps, exercise, in addition to participating in the peer support via the chat function. Participants will also receive regular care and follow up in community pharmacies for support.
Participants will be issued a fitness tracker, a Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (weekly bite-sized content over 4 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
Active Comparator: Usual care arm
The control group will be a "usual care" condition in which participants are free to seek any assistance for their medical care during the study period. Participants will be given physical tracking sheets to record their food intake, weight, steps and exercises.
Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of mobile app assessed by the engagement rate with the mobile app
Time Frame: 1 month
Engagement rate with the mobile app will be measured via time spend on using the app functions, measured in hours.
1 month
Acceptability of mobile app assessed by a semi-structured interview
Time Frame: 1 month
Semi-structured interview focusing on users experience will be conducted post-intervention.
1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in health related quality of life as accessed by EuroQol (EQ-5D-5L)
Time Frame: Baseline, 1 month
The questionnaire assess patient's health state in 5 dimensions- anxiety/depression, mobility, self-care, usual activities, pain/discomfort. Each dimension can be scored from 1 - 5, summing up to a total score of between 5 - 25. A lower score representing a better health state.
Baseline, 1 month
Change in dietary practice
Time Frame: Baseline, 1 month
3-Day diet recall to assess changes in food intake
Baseline, 1 month
Change in physical activity
Time Frame: Baseline, 1 month
Physical Activity Questionnaire (short form) (IPAQ) to obtain internationally comparable data on health-related physical activity. Time spent on physical activities will be measured and converted into metabolic equivalent for task (MET). A lower MET indicates a lower physical activity level.
Baseline, 1 month
Change in blood pressure
Time Frame: Baseline, 1 month
Systolic and diastolic pressures will be collected during the study period, unit in mmHg
Baseline, 1 month
Change in lipid profile
Time Frame: Baseline, 1 month
HDL, LDL, triglycerides and total cholesterol levels will be collected, unit in mmol/L
Baseline, 1 month
Change in knowledge, attitude and practice towards prediabetes
Time Frame: Baseline, 1 month
Knowledge Attitude Practice-Prediabetes Assessment Questionnaire (KAP-PAQ) questionnaire will be administered pre- and post intervention. The minimum total score is 14 while the maximum total score is 91. A higher score indicating a better knowledge, attitude and practice.
Baseline, 1 month
Change in weight
Time Frame: Baseline, 1 month
Weight Loss by % of change and total weight change (kg).
Baseline, 1 month
Change in body fat composition
Time Frame: Baseline, 1 month
Body fat composition change measured in % change.
Baseline, 1 month
Change in waist-to-hip ratio
Time Frame: Baseline, 1 month
Waist circumference and hip circumference measured in centimetres.
Baseline, 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Shaun Lee, PhD, Monash University Malaysia
  • Principal Investigator: Chun Wie Chong, PhD, Monash University Malaysia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2022

Primary Completion (Actual)

November 30, 2024

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

December 15, 2021

First Submitted That Met QC Criteria

January 14, 2022

First Posted (Actual)

January 28, 2022

Study Record Updates

Last Update Posted (Actual)

May 8, 2025

Last Update Submitted That Met QC Criteria

May 5, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

We plan to share any related individual participant data within reasonable request which can be obtained from the principal investigators

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on PreDiabetes

Clinical Trials on Digital health supported

Subscribe